-+ 0.00%
-+ 0.00%
-+ 0.00%

RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) COMBINATION DEMONSTRATES 77% OVERALL RESPONSE RATE IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED HEAD AND NECK CANCER

Reuters·10/25/2026 13:47:01